Inhibiting PI3Kα signalling with the PI3Kα inhibitor (PI3Kαi) alpelisib in combination with the ER degrader fulvestrant improved progression-free survival in patients with confirmed tumour-tissue PIK3CA mutations7. The gene discussed is PIK3CA; the disease is neoplasm.